Home > Healthcare > Medical Devices > Diagnostic Devices > Cystatin C Assay Market

Cystatin C Assay Market Share

Report ID: GMI7697
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Cystatin C Assay Market Share

The cystatin C assay industry is consolidated, with key players including, Roche Diagnostics Limited, Siemens Healthineers AG, Abbott Laboratories, Beckman Coulter (Danaher Corporation), and others dominating the market space. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market shares. For instance, in January 2021, Roche acquired GenMark, which is involved in the development and manufacturing of cystatin C assays. This acquisition strengthened Roche's position in the cystatin C assay industry and expanded its product portfolio.

Cystatin C Assay Market Companies

Some of the eminent market participants operating in the cystatin C assay industry include:

Roche Diagnostics Limited
Siemens Healthineers AG
Abbott Laboratories
Beckman Coulter (Danaher Corporation)
Thermo Fisher Scientific Inc
bioMérieux SA
Sysmex Corporation
Randox Laboratories
DiaSorin
Agilent Technologies Inc.
Bio-Rad Laboratories Inc
Abcam Plc
DiaSys Diagnostic Systems GmbH
Sino Biological, Inc.
Bio-Techne Corporation

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Market size for cystatin C assay was USD 269.6 million in 2023 and is expected to reach USD 522.6 billion by 2032 due to the increasing prevalence of chronic kidney diseases and in the surging need for early diagnosis, monitoring, and kidney stone management worldwide.

Cystatin C assay industry size from the kits products segment recorded USD 116.8 million in 2023 and is expected to register an appreciable CAGR from 2024-2032 owing to their prominent role in providing laboratories and healthcare facilities with convenient and ready-to-use solutions.

U.S. industry size for cystatin C assay recorded USD 102.4 million in 2023 due to the advanced healthcare infrastructure, widespread access to cutting-edge diagnostic technologies, and the increasing prevalence of chronic kidney diseases in the region.

Siemens Healthineers AG, Abbott Laboratories, Beckman Coulter (Danaher Corporation), Thermo Fisher Scientific Inc, bioM